药物相关性肺动脉高压
本文系统检索PubMed 1970年9月至2017年文献,初检853篇同行评议文章,排除599篇后综述了与肺动脉高压相关的治疗药物。涉及5-羟色胺代谢的药物(阿米雷司、芬氟拉明、苯氟雷司、苯丙醇胺、右芬氟拉明等食欲抑制剂及SSRI、色氨酸、锂)、干扰素α与索磷布韦、小分子酪氨酸激酶抑制剂(达沙替尼证据最强,被视为已确认病因)、单克隆抗体与免疫调节剂(曲妥珠单抗美坦新、利妥昔单抗、贝伐珠单抗、环孢素、来氟米特)、丁丙诺啡与可卡因、曲马多、化疗药(博来霉素、环磷酰胺、丝裂霉素增加肺静脉闭塞性疾病风险)等。作者结论:药物性肺动脉高压仅占大型注册系列病例的10.5%,支持证据通常有限,基于病例系列和观察性数据。
要点
- 药物性肺动脉高压仅占大型注册系列病例的10.5%,属罕见诊断,药物性病因更为少见。
- 达沙替尼在药物性肺动脉高压中证据最强,被视为已确认的病因。
- 食欲抑制剂(阿米雷司、芬氟拉明、苯氟雷司、苯丙醇胺、右芬氟拉明)是首个被认识到可引起肺动脉高压的药物类别,多数已在全球撤市。
- 烷化剂及类烷化剂(博来霉素、环磷酰胺、丝裂霉素)增加肺静脉闭塞性疾病风险,临床可能与肺动脉高压难以区分。
- 曲马多已被证实可导致严重、短暂且可逆的肺动脉高压;丁丙诺啡和可卡因被认定为潜在病因,机制不明。
研究设计与关键结果
- 系统检索PubMed 1970年9月至2017年文献,检索词为「drug induced pulmonary hypertension」,初检853篇同行评议文章(含病例报告),排除599篇涉及系统性高血压、慢阻肺、HIV、肺纤维化、替代鉴别诊断、治疗、基础科学、治疗不良反应及肺栓塞继发肺动脉高压的文章。
- 5-羟色胺代谢相关药物:食欲抑制剂(阿米雷司、芬氟拉明、苯氟雷司、苯丙醇胺、右芬氟拉明)是首个被认识到可引起肺动脉高压的药物类别,多数已在全球撤市;SSRI、色氨酸和锂也涉及肺动脉高压发生。
- 干扰素α和索磷布韦在具有其他危险因素(如HIV合并感染)的患者中与肺动脉高压发生相关;索磷布韦在具有多个危险因素的患者中关联2例肺动脉高压,其致病作用尚不清楚。
- 小分子酪氨酸激酶抑制剂中达沙替尼证据最强,被视为已确认病因;尼洛替尼、帕纳替尼、卡非佐米和鲁索替尼等较新药物 paradoxically 既与肺动脉高压病因相关又与治疗相关。
- 单克隆抗体和免疫调节治疗(曲妥珠单抗美坦新、利妥昔单抗、贝伐珠单抗、环孢素、来氟米特)仅有病例报告关联,无大型系列记录这些药物增加肺动脉高压患病率。
- 丁丙诺啡和可卡因被认定为肺动脉高压潜在病因,机制不明;曲马多已被证实可导致严重、短暂且可逆的肺动脉高压。
- 烷化剂及类烷化剂(博来霉素、环磷酰胺、丝裂霉素)增加肺静脉闭塞性疾病风险,临床可能与肺动脉高压难以区分;沙利度胺和紫杉醇也被涉及为潜在病因。
- 其他药物:鱼精蛋白与肝素结合时似乎可引起急性、可逆的肺动脉高压;胺碘酮也可通过已知不良反应导致肺动脉高压。
证据类型、等级与局限
- 证据类型:系统检索的综述,纳入病例报告、病例系列和观察性数据。
- 作者结论指出,尽管多种药物涉及肺动脉高压发生,支持证据通常有限,基于病例系列和观察性数据。
- 作者指出,即使在关联相对较强的药物中, predispose 个体发生肺动脉高压的因素尚未阐明。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者综述指出药物性肺动脉高压仅占大型注册系列病例的10.5%,临床遇肺动脉高压患者时应关注药物暴露史(食欲抑制剂、达沙替尼、干扰素α、索磷布韦、曲马多、丁丙诺啡、可卡因、烷化剂等)。
- 作者指出达沙替尼被视为药物性肺动脉高压的已确认病因,尼洛替尼、帕纳替尼、卡非佐米和鲁索替尼等较新药物既与病因相关又与治疗相关。
- 作者指出烷化剂及类烷化剂(博来霉素、环磷酰胺、丝裂霉素)增加肺静脉闭塞性疾病风险,临床可能与肺动脉高压难以区分。
- 作者指出曲马多可导致严重、短暂且可逆的肺动脉高压;鱼精蛋白与肝素结合时似乎可引起急性、可逆的肺动脉高压。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: While pulmonary arterial hypertension remains an uncommon diagnosis, various therapeutic agents are recognized as important associations. These agents are typically categorized into "definite", "likely", "possible", or "unlikely" to cause pulmonary arterial hypertension, based on the strength of evidence.
OBJECTIVE: This review will focus on those therapeutic agents where there is sufficient literature to adequately comment on the role of the agent in the pathogenesis of pulmonary arterial hypertension.
METHODS: A systematic search was conducted using PubMed covering the period September 1970- 2017. The search term utilized was "drug induced pulmonary hypertension". This resulted in the identification of 853 peer-reviewed articles including case reports. Each paper was then reviewed by the authors for its relevance. The majority of these papers (599) were excluded as they related to systemic hypertension, chronic obstructive pulmonary disease, human immunodeficiency virus, pulmonary fibrosis, alternate differential diagnosis, treatment, basic science, adverse effects of treatment, and pulmonary hypertension secondary to pulmonary embolism. Agents affecting serotonin metabolism (and related anorexigens): Anorexigens, such as aminorex, fenfluramine, benfluorex, phenylpropanolamine, and dexfenfluramine were the first class of medications recognized to cause pulmonary arterial hypertension. Although most of these medications have now been withdrawn worldwide, they remain important not only from a historical perspective, but because their impact on serotonin metabolism remains relevant. Selective serotonin reuptake inhibitors, tryptophan, and lithium, which affect serotonin metabolism, have also been implicated in the development of pulmonary arterial hypertension. Interferon and related medications: Interferon alfa and sofosbuvir have been linked to the development of pulmonary arterial hypertension in patients with other risk factors, such as human immunodeficiency virus co-infection. Antiviral therapies: Sofosbuvir has been associated with two cases of pulmonary artery hypertension in patients with multiple risk factors for its development. Its role in pathogenesis remains unclear. Small molecule tyrosine kinase inhibitors: Small molecule tyrosine kinase inhibitors represent a relatively new class of medications. Of these dasatinib has the strongest evidence in drug-induced pulmonary arterial hypertension, considered a recognized cause. Nilotinib, ponatinib, carfilzomib, and ruxolitinib are newer agents, which paradoxically have been linked to both cause and treatment for pulmonary arterial hypertension. Monoclonal antibodies and immune regulating medications: Several case reports have linked some monoclonal antibodies and immune modulating therapies to pulmonary arterial hypertension. There are no large series documenting an increased prevalence of pulmonary arterial hypertension complicating these agents; nonetheless, trastuzumab emtansine, rituximab, bevacizumab, cyclosporine, and leflunomide have all been implicated in case reports. Opioids and substances of abuse: Buprenorphine and cocaine have been identified as potential causes of pulmonary arterial hypertension. The mechanism by which this occurs is unclear. Tramadol has been demonstrated to cause severe, transient, and reversible pulmonary hypertension. Chemotherapeutic agents: Alkylating and alkylating-like agents, such as bleomycin, cyclophosphamide, and mitomycin have increased the risk of pulmonary veno-occlusive disease, which may be clinically indistinct from pulmonary arterial hypertension. Thalidomide and paclitaxel have also been implicated as potential causes. Miscellaneous medications: Protamine appears to be able to cause acute, reversible pulmonary hypertension when bound to heparin. Amiodarone is also capable of causing pulmonary hypertension by way of recognized side effects.
CONCLUSIONS: Pulmonary arterial hypertension remains a rare diagnosis, with drug-induced causes even more uncommon, accounting for only 10.5% of cases in large registry series. Despite several agents being implicated in the development of PAH, the supportive evidence is typically limited, based on case series and observational data. Furthermore, even in the drugs with relatively strong associations, factors that predispose an individual to PAH have yet to be elucidated.
参考来源
- McGee M, Whitehead N, Martin J, et al. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018. PMID: 29508628. doi:10.1080/15563650.2018.1447119
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。